Picard, C;
Nilsson, N;
Labonté, A;
Auld, D;
Rosa-Neto, P;
Alzheimer's Disease Neuroimaging Initiative;
Ashton, NJ;
... PREVENT-AD research group; + view all
(2021)
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
10.1002/alz.12442.
(In press).
Preview |
Text
Zetterberg_Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease_AOP.pdf - Published Version Download (837kB) | Preview |
Abstract
INTRODUCTION: We examine the role of brain apolipoprotein B (apoB) as a putative marker of early tau pathology and cognitive decline. METHODS: Cerebrospinal fluid (CSF) samples from cognitively normal and Alzheimer's disease (AD) participants were collected to measure protein levels of apoB and AD biomarkers amyloid beta (Aβ), t-tau and p-tau, as well as synaptic markers GAP43, SYNAPTOTAGMIN-1, synaptosome associated protein 25 (SNAP-25), and NEUROGRANIN. CSF apoB levels were contrasted with positron emission tomography (PET) scan measures of Aβ (18F-NAV4694) and Tau (flortaucipir) along with cognitive assessment alterations over 6 to 8 years. RESULTS: CSF apoB levels were elevated in AD participants and correlated with t-tau, p-tau, and the four synaptic markers in pre-symptomatic individuals. In the latter, CSF apoB levels correlated with PET flortaucipir-binding in entorhinal, parahippocampal, and fusiform regions. Baseline CSF apoB levels were associated with longitudinal visuospatial cognitive decline. DISCUSSION: CSF apoB markedly associates with early tau dysregulation in asymptomatic subjects and identifies at-risk individuals predisposed to develop visuospatial cognitive decline over time.
| Type: | Article |
|---|---|
| Title: | Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/alz.12442 |
| Publisher version: | https://doi.org/10.1002/alz.12442 |
| Language: | English |
| Additional information: | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2021 The Authors. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association. |
| Keywords: | Alzheimer's disease, PET scans, RBANS, apolipoprotein B, cerebrospinal fluid, synaptic markers, tau pathology |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10135817 |
Archive Staff Only
 |
View Item |
